Francoise de Craecker - 01 Jan 2026 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Director
Signature
/s/ David Kirske, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
01 Jan 2026
Net transactions value
$0
Form type
4
Filing time
05 Jan 2026, 16:06:13 UTC
Previous filing
10 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
de Craecker Francoise Director C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON /s/ David Kirske, attorney-in-fact 05 Jan 2026 0001887843

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XFOR Stock Option (right to buy) Award $0 +110,000 $0.000000 0 01 Jan 2026 Common Stock 110,000 $4.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.

Remarks:

Exhibit List: Exhibit 24 Power of Attorney